Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010

Eurosurveillance

Volumn 15, Issue 47, 2010, Pages

  Unemo, M ^a   Golparian, D ^a   Syversen, G ^b   Vestrheim, D F ^c,d   Moi, H ^c,d,e  

^a ÖREBRO UNIVERSITY   (Sweden)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; SPECTINOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; CASE REPORT; CONCENTRATION RESPONSE; DRUG TREATMENT FAILURE; DYSURIA; FOLLOW UP; GENE SEQUENCE; GONORRHEA; HETEROSEXUAL MALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NORWAY; POLYMORPHONUCLEAR CELL; SINGLE DRUG DOSE; TREATMENT DURATION; URETHRITIS;

EID: 78649801372     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/ese.15.47.19721-en     Document Type: Article

References (11)

1. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drugresistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther. 2009;7(7):821-834.
2. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother. 2009;10(4):555-577.
3. Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, et al. Threat to cefixime treatment of gonorrhea. Emerg Infect Dis. 2007;13(8):1275-1277.
4. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65(10):2141-2148.
5. Hjelmevoll SO, Olsen ME, Sollid JU, Haaheim H, Unemo M, Skogen V. A fast real-time polymerase chain reaction method for sensitive and specific detection of the Neisseria gonorrhoeae porA pseudogene. J Mol Diagn. 2006;8(5):574-581.
6. Unemo M, Sjöstrand A, Akhras M, Gharizadeh B, Lindbäck E, Pourmand N, et al. Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacin-resistant strain. APMIS. 2007;115(3):231-241.
7. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother. 2009;63(6):1142-1151.
8. Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: Association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother. 2007;51(6):2117-2122.
9. Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas R. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009;53(9):3744-3751.
10. WHO GASP Document. Rationale and applications for the current (2008) WHO panel of Neisseria gonorrhoeae for antimicrobial resistance surveillance for public health purposes, and instructions for their use. In: Technical document D007-0408-1#1 (2008) Sydney: WHO Collaborating Centre for STD.
11. Golparian D, Hellmark B, Fredlund H, Unemo M. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect. 2010;86(6):454-460.